First in Human Single Ascending Dose Study of MOR107
Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of MOR107 in Healthy Male Subjects and Pharmacodynamics in Healthy Male Subjects on a Low Sodium Diet
Sponsor: Alan Richardson
Terminated
Part 1 completed successfully. Part 2 not conducted.
Other Safety trials with similar outcome
A PHASE1 clinical study on Safety, this trial is terminated or withdrawn. The trial is conducted by Alan Richardson and has accumulated 6 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
▶ Show 1 earlier version
-
Apr 2017 — Mar 2018 [monthly]
Recruiting PHASE1
First recorded
Feb 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alan Richardson
- Quotient Clinical
For direct contact, visit the study record on ClinicalTrials.gov .